We're sorry, but this trial is no longer enrolling volunteers.
RTOG 1115: PHASE III TRIAL OF DOSE ESCALATED RADIATION THERAPY AND STANDARD ANDROGEN DEPRIVATION THERAPY (ADT) WITH A GNRH AGONIST VS. DOSE ESCALATED RADIATION THERAPY AND ENHANCED ADT WITH A GNRH AGONIST AND TAK-700 FOR MEN WITH HIGH RISK PROSTATE CANCER
- To evaluate the difference in overall survival of patients with clinically localized
prostate cancer with unfavorable prognostic features between a) standard treatment
(androgen-deprivation therapy [ADT] + radiotherapy) and b) standard treatment with the
addition of 24 months of steroid 17alpha-monooxygenase TAK-700 (TAK-700).
- To characterize differences between the treatment groups with respect to incidence of
unexpected grade ≥ 3 adverse events and/or clinically significant decrement in
patient-reported quality of life (QOL) among subjects treated with TAK-700.
- To compare rates and cumulative incidence of biochemical control (freedom from PSA
failure), local/regional progression, and distant metastases.
- To compare rate and cumulative incidence of clinical failure, defined as
prostate-specific antigen (PSA) > 25 ng/mL, documented local disease progression,
regional or distant metastasis, or initiation of ADT.
- To compare prostate cancer-specific survival and other-cause mortality.
- To compare the change in severity of fatigue as measured by the Patient-Reported
Outcome Measurement Information System (PROMIS) fatigue short form.
- To compare changes in patient-reported QOL as measured by Expanded Prostate Cancer
Index Composite (EPIC).
- To assess quality-adjusted survival using the EQ-5D.
- To compare nadir and average serum testosterone at 12 and 24 months during treatment.
- To compare changes in hemoglobin A1C, fasting glucose, and fasting insulin during 24
months of systemic treatment and during the first three years of follow-up.
- To compare changes in fasting lipid levels during 24 months of treatment and during the
first three years of follow-up.
- To compare changes in body mass index (BMI) during 24 months of treatment and during
the first three years of follow-up.
- To compare the incidence of adverse events ascertained via CTCAE version 4.
- To compare the rate of recovery of testosterone to > 230 ng/dL (accepted threshold for
supplementation) after 12 and 24 months of follow-up.
- To compare the median time to recovery of testosterone to > 230 ng/dL during the first
five years of follow-up.
- To assess cumulative incidence of relevant clinical survivorship endpoints including
new diagnosis of type 2 diabetes, coronary artery disease, myocardial infarction,
stroke, pulmonary embolism, deep vein thrombosis, or osteoporotic fracture.
OUTLINE: This is a multicenter, randomized study. Patients are stratified according to risk
group (see Disease Characteristics) and type of radiation therapy (RT) boost
(intensity-modulated RT (IMRT) vs brachytherapy). Patients are randomized to 1 of 2
- Arm I: Patients receive standard androgen suppression (AS) with a luteinizing
hormone-releasing hormone (LHRH) agonist (such as leuprolide, goserelin, buserelin, or
triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as
flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation
- Arm II: Patients receive the same standard AS with LHRH agonist and oral antiandrogen
as in arm 1. Patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO
twice daily (BID) for 2 years.
In both arms, patients undergo IMRT or 3D-conformal RT to the whole pelvis once daily, 5
days a week, for 6-8 weeks. Some patients also receive brachytherapy.
Quality of life is assessed via the Patient-Reported Outcome Measurement Information System
(PROMIS) Fatigue Scale, the Expanded Prostate Cancer Index Composite (EPIC-26), and the
EuroQol (EQ-5D) assessments at baseline and periodically during the study.
Serum may be collected from some patients for correlative studies.
After completion of study therapy, patients are followed every 3 months for 2 years, every 6
months for 1 year, and then annually thereafter.
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.
Inclusion and Exclusion Criteria
- Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days prior to registration at high risk for recurrence as determined by one of the following combinations (risk group):
- Gleason Score (GS) ≥ 9, PSA ≤ 150 ng/mL, any T stage
- GS ≥ 8, PSA < 20 ng/mL, T stage ≥ T2
- GS ≥ 8, PSA ≥ 20-150 ng/mL, any T stage
- GS ≥ 7, PSA ≥ 20-150 ng/mL, any T stage
- Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech), obtained prior to any luteinizing hormone-releasing hormone (LHRH) agonist or antiandrogen therapy, within 180 days of randomization
- Androgen deprivation therapy (ADT), such as LHRH agonists (e.g., goserelin, leuprolide), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethyl
- stilbestrol [DES]), or surgical castration (orchiectomy), may have been started prior to registration, provided that registration is within 50 days of beginning ADT; please note: if the patient has started ADT he will not be eligible to participate in the quality of life component of this study
- Clinically negative lymph nodes as established by imaging (abdominal and/or pelvic CT or abdominal and/or pelvic MRI), nodal sampling, or dissection within 90 days prior to registration
- Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are < 2.0 cm
- No distant metastases (M0) on bone scan within 90 days prior to registration
- Equivocal bone scan findings are allowed if plain films are negative for metastasis
- No definite evidence of metastatic disease
- Any patient undergoing brachytherapy must have transrectal ultrasound confirmation of prostate volume < 60 cc, American Urological Association (AUA) score ≤ 15 within 60 days of registration, and no history of prior transurethral resection of the prostate (TURP)
- Prior TURP is permitted for patients who receive external-beam radiotherapy (EBRT) only PATIENT CHARACTERISTICS:
- Height, weight, Zubrod performance status 0-1
- Absolute neutrophil count (ANC) ≥ 1,800 cells/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 8.0 g/dL (The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
- Serum creatinine < 2.0 mg/dL
- Creatinine clearance > 40 mL/minute
- Bilirubin < 1.5 x upper limit of normal (ULN)
- Alanine aminotranserase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN
- No PSA > 150 ng/mL
- Screening calculated ejection fraction ≥ ULN by multiple-gated acquisition (MUGA) scan or by echocardiogram
- Androgen deprivation therapy (ADT), such as LHRH agonists (e.g., goserelin, leuprolide), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or surgical castration (orchiectomy) may have been started prior to registration, provided that registration is within 50 days of beginning ADT.
- Patients, even if surgically sterilized (i.e., status post vasectomy), must agree to practice effective barrier contraception during the entire study treatment period and for 4 months (120 days) after the last dose of study drug
- No prior invasive malignancy (except non-melanoma skin cancer) unless disease-free or not requiring systemic therapy for a minimum of 3 years
- No known hypersensitivity to TAK-700 or related compounds
- No history of adrenal insufficiency
- No history of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of grade > 2 (NCI CTCAE, version 4.02) thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to registration
- Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed
- No New York Heart Association Class III or IV heart failure
- No ECG abnormalities of Q-wave infarction, unless identified 6 or more months prior to screening, or corrected QT (QTc) interval > 460 msec
- No prior allergic reaction to the drugs involved in this protocol
- No Cushing syndrome
- No severe chronic renal disease or chronic liver disease
- No uncontrolled hypertension despite appropriate medical therapy within 21 days prior to registration (blood pressure of greater than 150 mm Hg systolic and 90 mm Hg diastolic at 2 separate measurements no more than 60 minutes apart during screening visit)
- No serious infection within 14 days prior to registration
- No uncontrolled nausea, vomiting, or diarrhea (CTCAE grade ≥ 3) despite appropriate medical therapy at the time of registration
- No known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-700, including difficulty swallowing tablets PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior testosterone administration is allowed if last administered at least 90 days prior to registration
- No prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason
- No prior systemic chemotherapy for prostate cancer
- Prior chemotherapy for a different cancer is allowed
- No prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields
- No previous hormonal therapy for > 50 days
- No chronic treatment with glucocorticoids within one year
- No major surgery within 14 days prior to registration
- No other investigational agent
- No other anticancer therapy
- No concurrent hormonal therapies including estrogens or herbal products
- No concurrent ketoconazole or aminoglutethimide
- No chronic use of systemic corticosteroids, such as oral prednisone
- Veterans Administration Long Beach Medical Center, Long Beach, California, 90822
- Pomona Valley Hospital Medical Center, Pomona, California, 91767
- University of California At San Diego, San Diego, California, 92103
- Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, 95051
- Kaiser Permanente Cancer Treatment Center, South San Francisco, California, 94080
- UCSF-Mount Zion, San Francisco, California, 94115
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, 95682
- Mercy San Juan Medical Center, Carmichael, California, 95608
- Sutter General Hospital, Sacramento, California, 95816
- Sutter Solano Medical Center, Vallejo, California, 94589
- Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, 95687
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, 95661
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, 95603
- Rohnert Park Cancer Center, Rohnert Park, California, 94928
- Dixie Medical Center Regional Cancer Center, Saint George, Utah, 84770
- Intermountain Medical Center, Murray, Utah, 84157
- Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, 84106
- Arizona Oncology-Deer Valley Center, Phoenix, Arizona, 85027
- Arizona Oncology Services Foundation, Scottsdale, Arizona, 85260
- Rogue Valley Medical Center, Medford, Oregon, 97504
- Idaho Urologic Institute PA, Meridian, Idaho, 83642
- Saint Alphonsus Regional Medical Center, Boise, Idaho, 83706
- Poudre Valley Radiation Oncology, Fort Collins, Colorado, 80528
- Saint Francis Hospital, Federal Way, Washington, 98003
- Virginia Mason CCOP, Seattle, Washington, 98101
- Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, 59405
- The Klabzuba Cancer Center, Fort Worth, Texas, 76104
- Texas Oncology PA - Bedford, Bedford, Texas, 76022
- University of Texas Southwestern Medical Center, Dallas, Texas, 75390
- Texas Cancer Center-Sherman, Sherman, Texas, 75090
- Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, 77479
- Memorial Hermann Memorial City Medical Center, Houston, Texas, 77024
- M D Anderson Cancer Center, Houston, Texas, 77030
- UTMB Cancer Center at Victory Lakes, League City, Texas, 77573
- Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, 74136
- Sanford Bismarck Medical Center, Bismarck, North Dakota, 58501
- Sanford Medical Center-Fargo, Fargo, North Dakota, 58122
- The Nebraska Medical Center, Omaha, Nebraska, 68198
- Kansas City Cancer Centers-Southwest, Overland Park, Kansas, 66210
- Kansas City Cancer Center - South, Kansas City, Missouri, 64131
- Kansas City Cancer Center-Lee's Summit, Lee's Summit, Missouri, 64064
- Mercy Hospital Springfield, Springfield, Missouri, 65804
- Siteman Cancer Center - Saint Peters, Saint Peters, Missouri, 63376
- Barnes-Jewish West County Hospital, Saint Louis, Missouri, 63141
- Missouri Baptist Medical Center, Saint Louis, Missouri, 63131
- Siteman Cancer Center-South County, Saint Louis, Missouri, 63129
- Washington University School of Medicine, Saint Louis, Missouri, 63110
- Southeast Cancer Center, Cape Girardeau, Missouri, 63703
- Sanford Clinic North-Bemidgi, Bemidji, Minnesota, 56601
- Saint Luke's Hospital of Duluth, Duluth, Minnesota, 55805
- Gundersen Lutheran, La Crosse, Wisconsin, 54601
- Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226
- Appleton Medical Center, Appleton, Wisconsin, 54911
- Columbia Saint Mary's Hospital - Ozaukee, Mequon, Wisconsin, 53097
- Wheaton Franciscan Cancer Care - All Saints, Racine, Wisconsin, 53405
- Columbia Saint Mary's Water Tower Medical Commons, Milwaukee, Wisconsin, 53211
- Saint Mary's Hospital, Green Bay, Wisconsin, 54303
- Saint Vincent Hospital, Green Bay, Wisconsin, 54301
- Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, 53295
- Bay Area Medical Center, Marinette, Wisconsin, 54143
- OSF Saint Francis Medical Center, Peoria, Illinois, 61637
- Decatur Memorial Hospital, Decatur, Illinois, 62526
- Weiss Memorial Hospital, Chicago, Illinois, 60640
- Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121
- Touro Infirmary, New Orleans, Louisiana, 70115
- The Kirklin Clinic at Acton Road, Birmingham, Alabama, 35243
- Radiation Oncology Associates PC, Fort Wayne, Indiana, 46804
- Parkview Hospital Randallia, Fort Wayne, Indiana, 46805
- University of Cincinnati, Cincinnati, Ohio, 45267
- University of Kentucky, Lexington, Kentucky, 40536
- Northern Michigan Regional Hospital, Petoskey, Michigan, 49770
- McLaren Cancer Institute-Owosso, Owosso, Michigan, 48867
- Piedmont Hospital, Atlanta, Georgia, 30309
- Grady Health System, Atlanta, Georgia, 30303
- Emory University/Winship Cancer Institute, Atlanta, Georgia, 30322
- Atlanta VA Medical Center, Decatur, Georgia, 30033